SCHEMBL2805002

SCHEMBL2805002

O=C(Nc1cccc(Cl)c1)N1CCc2c(cnc3[nH]ncc23)C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAK1 Q13153 4/20 0.60
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
CASP3 P42574 1/20 0.59
SENP8 Q96LD8 1/20 0.59
SENP7 Q9BQF6 1/20 0.59
SENP6 Q9GZR1 1/20 0.59
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
ALDH1A1 P00352 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
RECQL P46063 1/20 0.49
MAPT P10636 3/20 0.47
KDM4E B2RXH2 1/20 0.47
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
FAAH O00519 2/20 0.46
LIMK1 P53667 2/20 0.46
LIMK2 P53671 2/20 0.46
GPR142 Q7Z601 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2806010 0.88 TRPV1 (0.56) PAK1NPC1RAB9ACASP3SENP8
SCHEMBL2805561 0.88 KDR (0.51) PAK1NPC1RAB9ACASP3SENP8
SCHEMBL2803952 0.88 TRPV1 (0.56) PAK1NPC1RAB9ACASP3SENP8
SCHEMBL12342043 0.88 MEN1 (0.55) PAK1MEN1KMT2AMAPTGAA
SCHEMBL2486602 0.88 RAB9A (0.55) PAK1NPC1RAB9AMEN1KMT2A
SCHEMBL2802876 0.88 PAK1 (0.48) PAK1NPC1RAB9ACASP3SENP8
SCHEMBL2487737 0.87 NPC1 (0.49) PAK1NPC1RAB9ACASP3SENP8
SCHEMBL2806850 0.87 RAB9A (0.60) PAK1NPC1RAB9ACASP3SENP8
SCHEMBL2802581 0.87 NAMPT (0.55) PAK1NPC1RAB9ACASP3SENP8
SCHEMBL2803705 0.87 MAPT (0.51) PAK1MAPTGPR142LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 PAK1 717/4885NPC1 205/4885RAB9A 1240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.